Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Htut · SciRah

Researcher profile · Semantic Scholar

M. Htut

Share profile

M. Htut — researcher profile on SciRah

h-index: 33
Works: 154
Citations: 4,997

Most-cited papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
J. Berdeja, D. Madduri, S. Usmani, A. Jakubowiak +32 more
2021The Lancet1,347 citations
Semantic Scholar
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
T. Martin, S. Usmani, J. Berdeja, M. Agha +24 more
2022Journal of Clinical Oncology508 citations Open access
Semantic Scholar
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
S. Mailankody, J. Matous, S. Chhabra, M. Liedtke +14 more
2023Nature Medicine229 citations
Semantic Scholar
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Natalie S. Callander, Muhamed Baljevic, Kehinde U. Adekola, Larry D. Anderson +25 more
2022The Journal of the National Comprehensive Cancer Network221 citations
Semantic Scholar
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K. Kumar, Natalie S. Callander, Kehinde U. Adekola, Larry D. Anderson +31 more
2023The Journal of the National Comprehensive Cancer Network146 citations Open access
Semantic Scholar
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.
S. Sidana, Krina K. Patel, Lauren C. Peres, R. Bansal +34 more
2024Blood141 citations Open access
Semantic Scholar
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, T. Martin, Yi Lin, Adam D. Cohen +29 more
2025Journal of Clinical Oncology130 citations Open access
Semantic Scholar
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Yi Lin, T. Martin, S. Usmani, J. Berdeja +16 more
2023Journal of Clinical Oncology96 citations
Semantic Scholar
Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
T. Martin, S. Usmani, J. Berdeja, A. Jakubowiak +24 more
2021Blood56 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K. Kumar, Natalie S. Callander, Kehinde U. Adekola, Larry D. Anderson +31 more
2025The Journal of the National Comprehensive Cancer Network52 citations
Semantic Scholar
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
S. Bal, M. Htut, O. Nadeem, Larry D. Anderson +16 more
2023Blood49 citations Open access
Semantic Scholar
A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Doris K. Hansen, Lauren C. Peres, D. Dima, Alicia Richards +48 more
2025Journal of Clinical Oncology48 citations
Semantic Scholar
Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
M. Rainone, Dat Ngo, John H. Baird, L. Budde +3 more
2022Blood Advances48 citations Open access
Semantic Scholar
Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience
T. Kourelis, R. Bansal, J. Berdeja, David S. Siegel +16 more
2023Transplantation and Cellular Therapy45 citations Open access
Semantic Scholar
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
S. Mailankody, M. Liedtke, S. Sidana, J. Matous +17 more
2021Blood42 citations Open access
Semantic Scholar
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Shaji K. Kumar, N. Callander, K. Adekola, Larry D. Anderson +25 more
2023The Journal of the National Comprehensive Cancer Network39 citations
Semantic Scholar
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K. Kumar, Natalie S. Callander, Kehinde U. Adekola, Larry D. Anderson +32 more
2024The Journal of the National Comprehensive Cancer Network38 citations Open access
Semantic Scholar
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
S. Sidana, H. Hosoya, Alexandria M. Jensen, Lawrence Liu +15 more
2023Blood Cancer Journal37 citations Open access
Semantic Scholar
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma
Yeu-Ong Shin, S. Pak, M. Mei, Yan Wang +14 more
2023American journal of hematology/oncology36 citations Open access
Semantic Scholar
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
T. Martin, Yi Lin, M. Agha, A. Cohen +19 more
2022The Lancet Haematology31 citations
Semantic Scholar
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.
Shaji K. Kumar, Natalie S. Callander, Kehinde U. Adekola, Larry D. Anderson +33 more
2026The Journal of the National Comprehensive Cancer Network28 citations
Semantic Scholar
Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
A. Kumar, S. Atallah-Yunes, Sridevi Rajeeve, A. Abdelhak +30 more
2024Blood26 citations
Semantic Scholar
Clonal Hematopoiesis is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-cell (CART) Therapy.
S. Goldsmith, G. Shouse, F. Wong, A. Bosworth +10 more
2024Transplantation and Cellular Therapy25 citations Open access
Semantic Scholar
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Doris K. Hansen, K. Patel, L. Peres, M. Kocoglu +16 more
2023Journal of Clinical Oncology24 citations
Semantic Scholar
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
S. Bal, Larry D. Anderson, O. Nadeem, J. Berdeja +16 more
2024Blood23 citations
Semantic Scholar
Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Study
M. Rosenzweig, Joycelynne Palmer, N. Tsai, T. Synold +15 more
2020Leukemia and Lymphoma22 citations Open access
Semantic Scholar
S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
N. Munshi, T. Martin, S. Usmani, J. Berdeja +16 more
2023HemaSphere16 citations Open access
Semantic Scholar
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
K. Ramasamy, A. Nooka, H. Quach, M. Htut +14 more
2021Blood Cancer Journal15 citations Open access
Semantic Scholar
Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.
T. Kourelis, R. Bansal, K. Patel, J. Berdeja +13 more
2022Journal of Clinical Oncology14 citations
Semantic Scholar
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
A. Cohen, P. Hari, M. Htut, J. Berdeja +18 more
2022Clinical Lymphoma, Myeloma & Leukemia14 citations Open access
Semantic Scholar
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
M. Htut, B. Dhakal, A. Cohen, T. Martin +12 more
2023Clinical Lymphoma, Myeloma & Leukemia13 citations Open access
Semantic Scholar
Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
S. Mailankody, J. Matous, M. Liedtke, S. Sidana +15 more
2022Blood12 citations Open access
Semantic Scholar
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
D. Pan, J. Kaufman, M. Htut, M. Agrawal +9 more
2021Cancer Medicine11 citations Open access
Semantic Scholar
Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia
Gliceida M. Galarza Fortuna, Lauren C. Peres, Elena Nazarenko, Andre De Menezes Silva Corraes +32 more
2025Blood Advances10 citations
Semantic Scholar
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
S. Bal, M. Htut, J. Berdeja, Larry D. Anderson +14 more
2024Blood10 citations
Semantic Scholar
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen
Raya Aliakbar, Olga V. Manouvakhova, Cindy K. Wong, M. Htut +5 more
2024Frontiers in Immunology9 citations Open access
Semantic Scholar
S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
S. Bal, J. Berdeja, M. Htut, M. Koçoğlu +13 more
2023HemaSphere9 citations Open access
Semantic Scholar
Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma
S. Midha, A. Gurumurthi, Patrick Costello, R. Redd +27 more
2023Blood7 citations Open access
Semantic Scholar
Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).
L. Costa, S. Mailankody, P. Shaughnessy, P. Hari +10 more
20216 citations
Semantic Scholar
Toxicities Associated with Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma
N. Nathwani, Joycelynne Palmer, T. Synold, B. Salehian +13 more
2020Clinical Lymphoma, Myeloma & Leukemia6 citations Open access
Semantic Scholar
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.
S. Bal, M. Htut, O. Nadeem, Larry D. Anderson +17 more
2026Blood5 citations Open access
Semantic Scholar
Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Luciano J. Costa, A. Oriol, D. Dytfeld, S. Manier +26 more
2025Blood5 citations
Semantic Scholar
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
Murali Janakiram, Lawrence Liu, S. Goldsmith, A. Borogovac +5 more
2025Blood Cancer Journal5 citations Open access
Semantic Scholar
Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis
R. Popat, Oliver Morjaria, C. Tan, Saad Z. Usmani +21 more
2025Blood4 citations
Semantic Scholar
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
P. Voorhees, Thomas G. Martin, Yi Lin, Adam D. Cohen +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
S. Jagannath, T. Martin, S. Usmani, J. Berdeja +16 more
2023Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
Y. Lin, T. Martin, J. Berdeja, A. Jakubowiak +16 more
2022HemaSphere3 citations Open access
Semantic Scholar
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
C. Tan, Saad Z. Usmani, A. Derkach, Andre De Menezes Silva Corraes +27 more
2026Blood Advances2 citations Open access
Semantic Scholar
Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
S. Bal, Luciano J. Costa, N. Bahlis, M. Htut +12 more
2025Blood2 citations
Semantic Scholar
Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.
Murali Janakiram, Jack Khouri, Omar Castaneda, L. Shune +23 more
2024Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Berdeja×17
Invite
J. Berdeja — researcher profile on SciRah
S. Sidana×13
Invite
S. Sidana — researcher profile on SciRah
D. Madduri×12
Invite
D. Madduri — researcher profile on SciRah
A. Jakubowiak×11
Invite
A. Jakubowiak — researcher profile on SciRah

×11

Invite

A. Cohen — researcher profile on SciRah

Invite

D. Sborov — researcher profile on SciRah

Invite

Tzu-Min Yeh — researcher profile on SciRah

Invite

C. Jackson — researcher profile on SciRah

Invite

A. Lesokhin — researcher profile on SciRah

Invite

A. Deol — researcher profile on SciRah

Invite

T. Martin — researcher profile on SciRah

S. Jagannath×8

Invite

S. Jagannath — researcher profile on SciRah